Have a feature idea you'd love to see implemented?
Let us know!
VCYT Veracyte Inc
Price (delayed)
$38.94
Market cap
$3.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.13
Enterprise value
$2.76B
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other
Highlights
Veracyte's net income has surged by 83% QoQ and by 81% YoY
The EPS has surged by 82% since the previous quarter and by 81% year-on-year
The debt has grown by 43% YoY but it has contracted by 5% from the previous quarter
Key stats
What are the main financial stats of VCYT
Market
Valuations
Earnings
Shares outstanding
77.5M
Market cap
$3.02B
Enterprise value
$2.76B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.54
Price to sales (P/S)
7.05
EV/EBIT
N/A
EV/EBITDA
137.93
EV/Sales
6.49
Revenue
$425.33M
EBIT
-$8.17M
EBITDA
$20.03M
Free cash flow
$56.48M
Per share
Balance sheet
Liquidity
EPS
-$0.13
Free cash flow per share
$0.73
Book value per share
$15.31
Revenue per share
$5.52
TBVPS
$5.25
Total assets
$1.28B
Total liabilities
$98.98M
Debt
$19.69M
Equity
$1.18B
Working capital
$286.54M
Debt to equity
0.02
Current ratio
5.08
Quick ratio
4.61
Net debt/EBITDA
-12.76
Margins
Efficiency
Dividend
EBITDA margin
4.7%
Gross margin
68.4%
Net margin
-2.2%
Operating margin
-5.5%
Return on assets
-0.8%
Return on equity
-0.8%
Return on invested capital
-11.2%
Return on capital employed
-0.7%
Return on sales
-1.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VCYT stock price
How has the Veracyte stock price performed over time
Intraday
-0.66%
1 week
5.13%
1 month
17.57%
1 year
54.65%
YTD
41.55%
QTD
14.39%
Financial performance
How have Veracyte's revenue and profit performed over time
Revenue
$425.33M
Gross profit
$291.13M
Operating income
-$23.54M
Net income
-$9.27M
Gross margin
68.4%
Net margin
-2.2%
The net margin has soared by 85% YoY and by 84% from the previous quarter
Veracyte's net income has surged by 83% QoQ and by 81% YoY
The operating margin has soared by 67% from the previous quarter and by 66% YoY
The operating income has soared by 65% from the previous quarter and by 58% YoY
Growth
What is Veracyte's growth rate over time
Valuation
What is Veracyte stock price valuation
P/E
N/A
P/B
2.54
P/S
7.05
EV/EBIT
N/A
EV/EBITDA
137.93
EV/Sales
6.49
The EPS has surged by 82% since the previous quarter and by 81% year-on-year
The P/B is 41% above the last 4 quarters average of 1.8 but 9% below the 5-year quarterly average of 2.8
The equity has grown by 12% YoY and by 3.8% from the previous quarter
The P/S is 38% above the last 4 quarters average of 5.1 but 31% below the 5-year quarterly average of 10.2
Veracyte's revenue has increased by 24% YoY and by 6% QoQ
Efficiency
How efficient is Veracyte business performance
The return on sales has surged by 87% year-on-year and by 86% since the previous quarter
VCYT's return on invested capital has surged by 86% since the previous quarter and by 85% year-on-year
The company's return on equity has surged by 84% QoQ and by 83% YoY
The ROA has soared by 83% from the previous quarter and by 81% YoY
Dividends
What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VCYT.
Financial health
How did Veracyte financials performed over time
The total liabilities has grown by 40% YoY but it has contracted by 2.8% from the previous quarter
The company's quick ratio rose by 16% QoQ and by 9% YoY
The debt is 98% less than the equity
VCYT's debt to equity has surged by 100% year-on-year
The debt has grown by 43% YoY but it has contracted by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.